227 related articles for article (PubMed ID: 31931649)
21. Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison.
Chu E; Schulman KL; McKenna EF; Cartwright T
Clin Colorectal Cancer; 2010 Oct; 9(4):229-37. PubMed ID: 20920995
[TBL] [Abstract][Full Text] [Related]
22. Myocardial Ischemia Induced by 5-Fluorouracil: A Prospective Electrocardiographic and Cardiac Biomarker Study.
Dyhl-Polk A; Schou M; Vistisen KK; Sillesen AS; Serup-Hansen E; Faber J; Klausen TW; Bojesen SE; Vaage-Nilsen M; Nielsen DL
Oncologist; 2021 Mar; 26(3):e403-e413. PubMed ID: 32959474
[TBL] [Abstract][Full Text] [Related]
23. 5-Fluorouracil Rechallenge After Cardiotoxicity.
Desai A; Mohammed T; Patel KN; Almnajam M; Kim AS
Am J Case Rep; 2020 Aug; 21():e924446. PubMed ID: 32860674
[TBL] [Abstract][Full Text] [Related]
24. 5-Fluorouracil-related Cardiotoxicity; Findings From Five Randomized Studies of 5-Fluorouracil-based Regimens in Metastatic Colorectal Cancer.
Abdel-Rahman O
Clin Colorectal Cancer; 2019 Mar; 18(1):58-63. PubMed ID: 30470591
[TBL] [Abstract][Full Text] [Related]
25. The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC).
Ng M; Cunningham D; Norman AR
Eur J Cancer; 2005 Jul; 41(11):1542-6. PubMed ID: 15978800
[TBL] [Abstract][Full Text] [Related]
26. Adverse events associated with bevacizumab and chemotherapy in older patients with metastatic colorectal cancer.
Shankaran V; Mummy D; Koepl L; Blough D; Yim YM; Yu E; Ramsey S
Clin Colorectal Cancer; 2013 Sep; 12(3):204-213.e1. PubMed ID: 23276520
[TBL] [Abstract][Full Text] [Related]
27. [Cardiotoxicity induced by 5-fluorouracil or capecitabine].
Jensen SA; Baeksgaard L; Petersen LN; Reiter L; Sørensen JB
Ugeskr Laeger; 2010 Jan; 172(1):48-51. PubMed ID: 20056096
[TBL] [Abstract][Full Text] [Related]
28. Severe sequence-specific toxicity when capecitabine is given after Fluorouracil and leucovorin.
Hennig IM; Naik JD; Brown S; Szubert A; Anthoney DA; Jackson DP; Melcher AM; Crawford SM; Bradley C; Brown JM; Seymour MT
J Clin Oncol; 2008 Jul; 26(20):3411-7. PubMed ID: 18612156
[TBL] [Abstract][Full Text] [Related]
29. Treatment of advanced colorectal cancer in a patient with cardiotoxic reactions to 5-fluorouracil and capecitabine using suboptimal doses.
Cioffi JH; Estes DJ; Florou V; Ardalan B
BMJ Case Rep; 2017 Nov; 2017():. PubMed ID: 29183892
[TBL] [Abstract][Full Text] [Related]
30. Capecitabine Versus Continuous Infusion Fluorouracil for the Treatment of Advanced or Metastatic Colorectal Cancer: a Meta-analysis.
Wu Z; Deng Y
Curr Treat Options Oncol; 2018 Nov; 19(12):77. PubMed ID: 30483908
[TBL] [Abstract][Full Text] [Related]
31. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.
Cassidy J; Twelves C; Van Cutsem E; Hoff P; Bajetta E; Boyer M; Bugat R; Burger U; Garin A; Graeven U; McKendric J; Maroun J; Marshall J; Osterwalder B; Pérez-Manga G; Rosso R; Rougier P; Schilsky RL;
Ann Oncol; 2002 Apr; 13(4):566-75. PubMed ID: 12056707
[TBL] [Abstract][Full Text] [Related]
32. Managing life-threatening 5-fluorouracil cardiotoxicity.
Boldig K; Ganguly A; Kadakia M; Rohatgi A
BMJ Case Rep; 2022 Oct; 15(10):. PubMed ID: 36253013
[TBL] [Abstract][Full Text] [Related]
33. Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients.
Matsumoto N; Kubota Y; Ishida H; Sekido M; Ohkuma R; Ishiguro T; Hirasawa Y; Ariizumi H; Tsunoda T; Ikusue T; Kobayashi K; Hisamatsu A; Toshima H; Shimada K; Fujita KI
Cancer Chemother Pharmacol; 2020 Jun; 85(6):1119-1128. PubMed ID: 32458030
[TBL] [Abstract][Full Text] [Related]
34. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety.
Luo HY; Li YH; Wang W; Wang ZQ; Yuan X; Ma D; Wang FH; Zhang DS; Lin DR; Lin YC; Jia J; Hu XH; Peng JW; Xu RH
Ann Oncol; 2016 Jun; 27(6):1074-1081. PubMed ID: 26940686
[TBL] [Abstract][Full Text] [Related]
35. Fluoropyrimidine-associated cardiotoxicity: revisited.
Saif MW; Shah MM; Shah AR
Expert Opin Drug Saf; 2009 Mar; 8(2):191-202. PubMed ID: 19309247
[TBL] [Abstract][Full Text] [Related]
36. Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity.
Deboever G; Hiltrop N; Cool M; Lambrecht G
Clin Colorectal Cancer; 2013 Mar; 12(1):8-14. PubMed ID: 23102544
[TBL] [Abstract][Full Text] [Related]
37. Fluoropyrimidine-Associated Cardiotoxicity: A Retrospective Case-Control Study.
Raber I; Warack S; Kanduri J; Pribish A; Godishala A; Abovich A; Orbite A; Dommaraju S; Frazer M; Peters ML; Asnani A
Oncologist; 2020 Mar; 25(3):e606-e609. PubMed ID: 32162823
[TBL] [Abstract][Full Text] [Related]
38. Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
Lee JJ; Kim TM; Yu SJ; Kim DW; Joh YH; Oh DY; Kwon JH; Kim TY; Heo DS; Bang YJ; Kim NK
Jpn J Clin Oncol; 2004 Jul; 34(7):400-4. PubMed ID: 15342667
[TBL] [Abstract][Full Text] [Related]
39. A systematic review of the safety profile of the different combinations of fluoropyrimidines and oxaliplatin in the treatment of colorectal cancer patients.
Baratelli C; Zichi C; Di Maio M; Brizzi MP; Sonetto C; Scagliotti GV; Tampellini M
Crit Rev Oncol Hematol; 2018 Feb; 122():21-29. PubMed ID: 29458787
[TBL] [Abstract][Full Text] [Related]
40. Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle.
Jensen SA; Hasbak P; Mortensen J; Sørensen JB
J Clin Oncol; 2010 Dec; 28(36):5280-6. PubMed ID: 21079148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
